2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. In summer, Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder Oxlumo was approved in the European Union and the US.
96 
Let's personalize your content